Clinical Scorecard: Innovative Strategies to Distinguish Graft-Versus-Leukemia Effects from Graft-Versus-Host Disease

At a Glance

Key Highlights

• Separation of GVL effects from GVHD is a central challenge in allo-HCT.
• Post-transplant relapse is associated with poor prognosis and driven by diverse mechanisms.
• Emerging strategies include selective modulation of T-cell trafficking and enhancement of tissue tolerance.
• Restoration of leukemia immunogenicity is a promising approach to prevent relapse.
• Research is focused on reshaping the tumor immune microenvironment to strengthen GVL activity.

Guideline-Based Recommendations

Diagnosis

• Utilize comprehensive immune profiling techniques to understand post-transplant relapse mechanisms.

Management

• Explore cellular therapies and selective immune modulation to manage GVHD while preserving GVL effects.

Monitoring & Follow-up

• Monitor for HLA loss and mutations as indicators of immune escape and relapse risk.

Risks

• Relapse after allo-HCT remains a significant risk, particularly due to immune escape mechanisms.

Patient & Prescribing Data

Patients with acute myeloid leukemia (AML) undergoing allo-HCT.

No universally effective standardized treatment strategy currently exists for post-transplant relapse.

Clinical Best Practices

• Identify and monitor HLA-related mutations in post-transplant relapse cases.
• Consider donor lymphocyte infusion or second transplant options carefully based on HLA haplotype status.

Related Resources & Content

• Innovative Strategies to Distinguish Graft-Versus-Leukemia Effects from Graft-Versus-Host Disease